Showing results (111-120 of 814) with videos related to

Sort By:
Pageof 82
BMJ Open Ophthalmology|July 14, 2020
Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case seriesMuna Ahmed, Christine Putri, Hibba Quhill, et al.
BMJ Open Ophthalmology|June 9, 2020
Complement factors and reticular pseudodrusen in intermediate age-related macular degeneration staged by multimodal imagingAnne M Lynch, Alan G Palestine, Brandie D Wagner, et al.
BMJ Open Ophthalmology|April 28, 2021
Dry eye: why artificial tears are not always the answerMinji Kim, Yonghoon Lee, Divy Mehra, et al.
BMJ Open Ophthalmology|September 6, 2021
Cluster of symptomatic silicone oil droplets following intravitreal injections: a 1-year observational studyMagne Sand Sivertsen, Heidrun Elisabeth Lode, Torleif Tollefsrud Gjølberg, et al.
BMJ Open Ophthalmology|August 16, 2021
Ophthalmic manifestations of proboscis lateralisEkta Singh Sahu, Pavan Humesh Shroff, Animesh Sahu, et al.
BMJ Open Ophthalmology|September 13, 2021
Strengthening retinopathy of prematurity screening and treatment services in Nigeria: a case study of activities, challenges and outcomes 2017-2020Dupe S Ademola-Popoola, Iretiola B Fajolu, Clare Gilbert, et al.
BMJ Open Ophthalmology|November 22, 2025
Enhancing AI-based diabetic retinopathy diagnosis through universal cross-camera image adaptationSanil Joseph, Xiaotian Chen, Chi Liu, et al.
BMJ Open Ophthalmology|January 14, 2026
Driver's licence in an adult population with good vision: an exploratory study in two longitudinal very low birthweight cohortsTora Sund Morken, Dordi Austeng, Maarit Kulmala, et al.
BMJ Open Ophthalmology|January 6, 2026
Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedemaZilin Wang, Junran Sun, Kun Liu, et al.
BMJ Open Ophthalmology|January 6, 2026
Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degenerationSigrid Balser, Björn Capsius, Rahul Hole, et al.
Pageof 82